For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Selling, general and administrative | 3,903 | 4,421* | 1,933 | 3,258 |
| Research and development | 2,034 | 1,603* | 597 | 1,064 |
| Change in fair value of contingent consideration | -4 | -3,467* | -37 | 16 |
| Total operating costs and expenses | 5,933 | 2,556 | 2,493 | 4,338 |
| Loss from operations | -5,933 | -2,556* | -2,493 | -4,338 |
| Change in fair value of convertible notes | -8,727 | -17,314* | -1,877 | -1,854 |
| Change in fair value of warrants | -4,656 | -19,552* | 236 | 542 |
| Loss on issuance of warrants | - | -18,911* | - | - |
| Loss on extinguishment of debt | -76 | - | - | - |
| Loss on derivative liability | 1,743 | 3,272* | - | - |
| Other income, net | 30 | 50* | 68 | 92 |
| Total other (loss) income, net | -5,860 | -19,895* | -2,045 | -2,304 |
| (loss) income before taxes | -11,793 | -22,452 | -4,538 | -6,642 |
| Net (loss) income | -11,793 | -22,452 | -4,538 | -6,642 |
| Basic EPS | -0.29 | -3.19 | -0.39 | -0.6 |
| Diluted EPS | -0.29 | -3.19 | -0.39 | -0.6 |
| Basic Average Shares | 40,614,087 | 7,039,006 | 11,634,946 | 11,090,809 |
| Diluted Average Shares | 40,614,087 | 7,039,006 | 11,634,946 | 11,090,809 |
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)